← Back to Search

Educational App for Hepatitis C

N/A

Recruiting

Led By Yu-Hsiang Hsieh, PhD

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

HCV positive without HCV RNA information

18 years or older

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 28 months

Awards & highlights

Study Summary

This trial will test the impact of a personalized educational app on people's knowledge and motivation related to hepatitis C care.

Who is the study for?

This trial is for adult patients at Johns Hopkins Hospital's Emergency Department who have tested positive for Hepatitis C but don't yet have HCV RNA testing information. It excludes minors, those unable to consent, prisoners, critically ill individuals, and patients with altered mental status.Check my eligibility

What is being tested?

The study tests an educational app designed to improve understanding of Hepatitis C among ED patients. The app provides personalized liver health information and aims to enhance patient knowledge and motivation regarding their care continuum from diagnosis through treatment.See study design

What are the potential side effects?

Since this trial involves the use of an educational app rather than a medical intervention or drug, traditional physical side effects are not expected. However, participants may experience stress or anxiety related to learning about their condition.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am positive for hepatitis C but don't have RNA details.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 28 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~28 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Linkage to care rate (days)

Secondary outcome measures

Change in HCV knowledge as assessed by True/False survey questions

Change in level of motivation to receive HCV care as assessed by a Likert Scale

Change in perceived barriers to HCV care as assessed by a Likert Scale

+3 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Patient-Centered Electronic App GroupExperimental Treatment1 Intervention

Patients assigned to the intervention group will receive individualized reports regarding patients' HCV disease progress/liver fibrosis staging by a Fibrosis-4 score using the personalized HCV educational app. The individualized report will also include comprehensive knowledge to fill the gap on general HCV information, natural history of the disease, and care and treatment, if there is any, as well as level of interest in receiving HCV care based on patients' response to the short survey questionnaires on the tablet. Patients will also receive the investigators' HCV program pamphlet regarding HCV infection and disease progression, treatment, as well as information regarding clinics available for HCV care in Baltimore. Patients will receive standard of care, routine HCV LTC services from the investigators' ED HCV LTC program staff.

Group II: Reference GroupActive Control1 Intervention

Patients assigned to the reference group will receive the investigators' current 'static' standard of care HCV program pamphlet regarding HCV infection and disease progression, treatment, as well as information regarding clinics available for HCV care in Baltimore City. Patients will also receive standard of care, routine HCV LTC services from the investigators' ED HCV LTC program staff.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor

2,262 Previous Clinical Trials

14,822,856 Total Patients Enrolled

18 Trials studying Hepatitis C

154,549 Patients Enrolled for Hepatitis C

Yu-Hsiang Hsieh, PhDPrincipal InvestigatorJohns Hopkins University

2 Previous Clinical Trials

400 Total Patients Enrolled

1 Trials studying Hepatitis C

200 Patients Enrolled for Hepatitis C

Media Library

Patient-Centered Electronic App Clinical Trial Eligibility Overview. Trial Name: NCT04162938 — N/A

Hepatitis C Research Study Groups: Patient-Centered Electronic App Group, Reference Group

Hepatitis C Clinical Trial 2023: Patient-Centered Electronic App Highlights & Side Effects. Trial Name: NCT04162938 — N/A

Patient-Centered Electronic App 2023 Treatment Timeline for Medical Study. Trial Name: NCT04162938 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can I register for this scientific experiment?

"This medical trial is recruiting 308 individuals between the ages of 18 and 100, who have been diagnosed with hepatitis c. To meet eligibility requirements, participants must also be current patients at Johns Hopkins Hospital ED and above the age of majority."

Answered by AI

Are there any age restrictions for participants in this experimental protocol?

"Adhering to the trial's requirements, patients must be 18 years or above and under 100."

Answered by AI

Can individuals still join the experiment at this point in time?

"This medical trial, as reported on clinicaltrials.gov, is currently recruiting patients. First posted 24th March 2022 and recently updated 29th March 2022."

Answered by AI

What is the maximum capacity for participation in this research?

"Affirmative, the information hosted on clinicaltrials.gov suggests that this trial is presently accepting participants. The clinical trial was first made available on March 24th 2022 and has since been updated as of March 29th 2022. A total of 308 individuals will be recruited across two distinct sites for participation in this study."

Answered by AI